Chronic Thromboembolic Pulmonary Hypertension, Post Thrombotic Syndrome, Venous Thrombosis
Conditions
Keywords
Post-thrombotic syndrome, Chronic thromboembolic pulmonary hypertension, Anticoagulation, Rivaroxaban
Brief summary
This prospective observational follow-up study is designed to assess the long-term outcomes after Venous thromboembolism (VTE) and to assess the effect of the new oral anticoagulant (NOAC) rivaroxaban on the prevalence of post-thrombotic syndrome (PTS). The study will not be testing any formal hypothesis.
Detailed description
This prospective observational follow-up study is designed to assess the long-term outcomes after VTE and to assess the effect of NOAC (rivaroxaban) on the prevalence of PTS. All patients diagnosed and treated for VTE at SØF from 01.01.2011 will be invited to participate in this study. Newly diagnosed patients will be recruited and followed-up according to the study schedule which is based on state of the art international guidelines. First follow-up will be performed at the end of treatment period, which is usually 3 or 6 months after an event of VTE, or at one year if patients will be put on permanent AC. Thereafter, patients will be followed-up annually for at least 5 years or up to the end of the study, i.e for 10 years. The primary endpoints of the study are the development of PTS and CTEPH after VTE. There will be 3 visits: at 3 or 6 months depending on the duration of AC, at 2 and 5 years, in addition to a visit for TTE at 6 months. Remaining follow-ups will be performed by phone or by mail. All patients with PE will be examined by TTE 6 months after the diagnosis of PE. Those with signs of PAH will be referred for further work-up to establish the presence or absence of CTEPH at specialized centres. Patients with DVT will be evaluated for PTS at 2 and 5 years and for CTEPH if they develop dyspnoea. As for part b of the primary objective, the study will allow inclusion of patients with previous DVT diagnosed after 01.01.11.
Interventions
None listed
Sponsors
Ostfold Hospital Trust
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with objectively verified first time DVT diagnosed after 01.01.11 for study A, OR objectively verified DVT and/or PE dignosed after 01.04.14 for study B. * 18 years of age * Signed informed written consent
Exclusion criteria
* Patients who refuse to consent * Patients who have been treated with other anticoagulants than thoose included in the study * Patients who can not participate due to logistic reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of post thrombotic syndrome and chronic thromboembolic pulmonary hypertension | 5 years | Determine the prevalence of post thrombotic syndrome as defined by Villalta score at 2- and 5 years in an unselected population of venous thromboembolism patients. Prevalence of chronic thromboembolic pulmonary hypertension in at 2- and 5 years in an unselected population of pulmonary embolism patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Post thrombotic syndrome according to CEAP | 9 years | PTS according to CEAP score |
| Risk factors | 9 years | Risk factors for venous thromboembolism |
| Bleeding | 9 years | Rate of bleeding during treatment with anticoagulation |
| Recurrence rate | 9 years | Recurrence rate during treatment and after discontinuation of anticoagulation. |
| Resource utilization | 9 years | Resource utilization (number of contacts with health care providers, INR tests during anticoagulation) |
| Severity of pulmonary embolism | 9 years | Severity of PE based on CT (Fredrikstad score) and troponin level. |
| Incidence of cancer | 9 years | Incidence of cancer after diagnosis of venous tromboembolism in screened and unscreened patients |
| Compliance in the use of Elastic compression stockings | 9 years | Compliance in the use of Elastic compression stockings |
| Mortality rate | 9 years | Mortality rate following deep vein thrombosis and /or pulmonary embolism. |
Countries
Norway
Contacts
Primary ContactKristin K Utne, MD
Backup ContactWaleed Ghanima, PhD
Outcome results
None listed